Cargando…

Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study

BACKGROUND AND AIMS: Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients' reported symptoms and expectations of the thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Jastrzębski, Dariusz, Kostorz‐Nosal, Sabina, Galle, Dagmara, Gałeczka‐Turkiewicz, Alicja, Warzecha, Joanna, Majewski, Sebastian, Piotrowski, Wojciech J., Ziora, Dariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432581/
https://www.ncbi.nlm.nih.gov/pubmed/37599655
http://dx.doi.org/10.1002/hsr2.1449
_version_ 1785091450505003008
author Jastrzębski, Dariusz
Kostorz‐Nosal, Sabina
Galle, Dagmara
Gałeczka‐Turkiewicz, Alicja
Warzecha, Joanna
Majewski, Sebastian
Piotrowski, Wojciech J.
Ziora, Dariusz
author_facet Jastrzębski, Dariusz
Kostorz‐Nosal, Sabina
Galle, Dagmara
Gałeczka‐Turkiewicz, Alicja
Warzecha, Joanna
Majewski, Sebastian
Piotrowski, Wojciech J.
Ziora, Dariusz
author_sort Jastrzębski, Dariusz
collection PubMed
description BACKGROUND AND AIMS: Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients' reported symptoms and expectations of the therapy. METHODS: Fifty‐two patients with confirmed IPF at a mean age of 65 ± 8.63 years (73% male) completed the following surveys at baseline and after 12 months of Pirfenidone treatment: Short Form Healthy Survey (SF‐36), St. George's Respiratory Questionnaire (SGRQ), Baseline Dyspnea Index (BDI), Fatigue Assessment Scale (FAS), Leicester Cough Questionnaire (LCQ), and Patient's Needs and Expectations Authors' Survey. RESULTS: The most important patients' needs were access to novel therapy, fast and easy access to health centers specializing in IPF treatment, and the improvement of the general condition or the maintenance of its level. These needs did not change with time, except for the significantly more important right of deciding on disease management after 12 months of treatment (p = 0.014). The quality of life per SF‐36, after 1 year of Pirfenidone treatment, significantly improved in the physical cumulative score (p = 0.004) and mental cumulative score (p = 0.003). Significant deteriorations were observed in bodily pain and vitality. For the remaining questionnaires (SGRQ, BDI, FAS, and LCQ), no significant changes in the course of the study were noticed. Around one in 10 patients subjected to Pirfenidone therapy had achieved general symptom improvement in all areas; that is, quality of life improvement as well as cough and dyspnea reduction. CONCLUSIONS: One year of antifibrotic treatment resulted in a general improvement in the quality of life per the SF‐36 questionnaire. Patients' expectations of disease management did not change; also, access to novel therapies and easy access to health centers specializing in IPF management remained their top needs.
format Online
Article
Text
id pubmed-10432581
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104325812023-08-18 Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study Jastrzębski, Dariusz Kostorz‐Nosal, Sabina Galle, Dagmara Gałeczka‐Turkiewicz, Alicja Warzecha, Joanna Majewski, Sebastian Piotrowski, Wojciech J. Ziora, Dariusz Health Sci Rep Original Research BACKGROUND AND AIMS: Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients' reported symptoms and expectations of the therapy. METHODS: Fifty‐two patients with confirmed IPF at a mean age of 65 ± 8.63 years (73% male) completed the following surveys at baseline and after 12 months of Pirfenidone treatment: Short Form Healthy Survey (SF‐36), St. George's Respiratory Questionnaire (SGRQ), Baseline Dyspnea Index (BDI), Fatigue Assessment Scale (FAS), Leicester Cough Questionnaire (LCQ), and Patient's Needs and Expectations Authors' Survey. RESULTS: The most important patients' needs were access to novel therapy, fast and easy access to health centers specializing in IPF treatment, and the improvement of the general condition or the maintenance of its level. These needs did not change with time, except for the significantly more important right of deciding on disease management after 12 months of treatment (p = 0.014). The quality of life per SF‐36, after 1 year of Pirfenidone treatment, significantly improved in the physical cumulative score (p = 0.004) and mental cumulative score (p = 0.003). Significant deteriorations were observed in bodily pain and vitality. For the remaining questionnaires (SGRQ, BDI, FAS, and LCQ), no significant changes in the course of the study were noticed. Around one in 10 patients subjected to Pirfenidone therapy had achieved general symptom improvement in all areas; that is, quality of life improvement as well as cough and dyspnea reduction. CONCLUSIONS: One year of antifibrotic treatment resulted in a general improvement in the quality of life per the SF‐36 questionnaire. Patients' expectations of disease management did not change; also, access to novel therapies and easy access to health centers specializing in IPF management remained their top needs. John Wiley and Sons Inc. 2023-08-16 /pmc/articles/PMC10432581/ /pubmed/37599655 http://dx.doi.org/10.1002/hsr2.1449 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Jastrzębski, Dariusz
Kostorz‐Nosal, Sabina
Galle, Dagmara
Gałeczka‐Turkiewicz, Alicja
Warzecha, Joanna
Majewski, Sebastian
Piotrowski, Wojciech J.
Ziora, Dariusz
Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study
title Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study
title_full Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study
title_fullStr Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study
title_full_unstemmed Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study
title_short Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study
title_sort expectations, symptoms, and quality of life before and after 1 year of pirfenidone treatment in patients with idiopathic pulmonary fibrosis: a single‐arm, open‐label nonrandomized study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432581/
https://www.ncbi.nlm.nih.gov/pubmed/37599655
http://dx.doi.org/10.1002/hsr2.1449
work_keys_str_mv AT jastrzebskidariusz expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy
AT kostorznosalsabina expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy
AT galledagmara expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy
AT gałeczkaturkiewiczalicja expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy
AT warzechajoanna expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy
AT majewskisebastian expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy
AT piotrowskiwojciechj expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy
AT zioradariusz expectationssymptomsandqualityoflifebeforeandafter1yearofpirfenidonetreatmentinpatientswithidiopathicpulmonaryfibrosisasinglearmopenlabelnonrandomizedstudy